1. Comparison of 12-Week Additional Effect Features of Formoterol Co-Inhalation and Tulobuterol Patch on Budesonide Inhalation in Elderly Patients With Asthma
- Author
-
Tetsuya Kawano, Tomoko Tsuchida-Yabe, Shinya Tomari, Susumu Fukahori, Jun Iriki, Chizu Fukushima, Yasushi Obase, Hiroshi Mukae, and Hiroto Matsuse
- Subjects
Agonist ,Budesonide ,lcsh:Immunologic diseases. Allergy ,Contraction (grammar) ,medicine.drug_class ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Immunology and Allergy ,impulse oscillometry ,Asthma ,Tulobuterol ,Inhalation ,business.industry ,transdermal delivery system ,medicine.disease ,lcsh:Otorhinolaryngology ,lcsh:RF1-547 ,Clinical Trial ,bronchial inflammation ,mini-Asthma Quality of Life Questionnaire ,fractional exhaled nitric oxide ,Impulse Oscillometry ,030228 respiratory system ,Otorhinolaryngology ,Anesthesia ,Formoterol ,business ,lcsh:RC581-607 ,medicine.drug ,prospective study - Abstract
Background For asthma strategy, to avoid the aggravation of bronchial inflammation and contraction, the long acting beta agonist (LABA) addition on inhaled corticosteroids (ICS) has been recommended. Objectives To know whether there is any clinical difference between the additional efficacies of Formoterol (FOR) and Tulobuterol (TUL) onto Budesonide (BUD) may be useful for the elderly patients’ asthma treatment strategy. Methods Eighteen outpatients with mild to moderate bronchial asthma with FEV1.0% Results The “Fres” of IOS was improved in FBC group (p = 0.03). The “emotion” domain of mini-AQLQ was improved in BUD + TUL group (p = 0.03). Conclusion By changing the drug formulation, the patch was superior in terms of satisfaction, but it was thought that the inhaled combination was superior in improving the respiratory function itself. It is necessary to pay attention to the characteristics of the patient when selecting treatment.
- Published
- 2020